Abstract
Thrombotic microangiopathy (TMA) is a disorder characterized by microvascular occlusion that can lead to thrombocytopenia, hemolytic anemia, and glomerular damage. Complement activation is the central event in most cases of TMA. Primary forms of TMA are caused by mutations in genes encoding components of the complement or regulators of the complement cascade. Recently, we and others have described a genetic form of TMA caused by mutations in the gene diacylglycerol kinase-ε (DGKE) that encodes the lipid kinase DGKε (Lemaire M, Fremeaux-Bacchi V, Schaefer F, Choi MR, Tang WH, Le Quintrec M, Fakhouri F, Taque S, Nobili F, Martinez F, Ji WZ, Overton JD, Mane SM, Nurnberg G, Altmuller J, Thiele H, Morin D, Deschenes G, Baudouin V, Llanas B, Collard L, Majid MA, Simkova E, Nurnberg P, Rioux-Leclerc N, Moeckel GW, Gubler MC, Hwa J, Loirat C, Lifton RP. Nat Genet 45: 531–536, 2013; Ozaltin F, Li BH, Rauhauser A, An SW, Soylemezoglu O, Gonul II, Taskiran EZ, Ibsirlioglu T, Korkmaz E, Bilginer Y, Duzova A, Ozen S, Topaloglu R, Besbas N, Ashraf S, Du Y, Liang CY, Chen P, Lu DM, Vadnagara K, Arbuckle S, Lewis D, Wakeland B, Quigg RJ, Ransom RF, Wakeland EK, Topham MK, Bazan NG, Mohan C, Hildebrandt F, Bakkaloglu A, Huang CL, Attanasio M. J Am Soc Nephrol 24: 377–384, 2013). DGKε is unrelated to the complement pathway, which suggests that unidentified pathogenic mechanisms independent of complement dysregulation may result in TMA. Studying Dgke knockout mice may help to understand the pathogenesis of this disease, but no glomerular phenotype has been described in these animals so far. Here we report that Dgke null mice present subclinical microscopic anomalies of the glomerular endothelium and basal membrane that worsen with age and develop glomerular capillary occlusion when exposed to nephrotoxic serum. We found that induction of cyclooxygenase-2 and of the proangiogenic prostaglandin E2 are impaired in Dgke null kidneys and are associated with reduced expression of the antithrombotic cell adhesion molecule platelet endothelial cell adhesion molecule-1/CD31 in the glomerular endothelium. Notably, prostaglandin E2 supplementation was able to rescue motility defects of Dgke knockdown cells in vitro and to restore angiogenesis in a test in vivo. Our results unveil an unexpected role of Dgke in the induction of cyclooxygenase-2 and in the regulation of glomerular prostanoids synthesis under stress.
Keywords: thrombotic microangiopathy, DGKE, hemolytic uremic syndrome
thrombotic microangiopathy (TMA) is a disorder associated with high mortality and substantial risk of progressing to chronic kidney disease (29). TMA is characterized by damage of the small vasculature of multiple organs, platelet aggregation, and arteriolar and capillary thrombosis, with consequent thrombocytopenia, microangiopathic hemolytic anemia, and organ damage (11). TMA is a common manifestation to several primary diseases, including hemolytic uremic syndrome (HUS), secondary or not to Shiga toxin-producing E. coli infections, thrombotic thrombocytopenic purpura, malignant hypertension, and preeclampsia. With the exception of thrombotic thrombocytopenic purpura, in which severe acute kidney injury and progression to chronic kidney disease are rare (15), kidney function is invariably affected in all of these conditions, suggesting that glomerular capillaries are particularly susceptible to develop thrombotic lesions (9, 17). Activation of the complement cascade is the central event of several forms of TMA (35). Infections from Shiga-like toxin-producing bacteria (Shiga-toxin E. coli-HUS), for example, result in excessive complement activation with consequent endothelial cell damage and exposure of tissue factor, thrombin, and other molecules that contribute to the formation of microthrombi (26). HUSs not associated with bacterial infection are defined atypical (atypical HUS) and are most often secondary to defects in genes encoding factors that participate in the complement cascade (30). Recently, our laboratory and others have described a genetic form of TMA that is caused by mutations in the gene that encodes the lipid kinase diacylglycerol kinase-ε (DGKε), and it is unrelated to the complement pathway (20, 31, 42). Recessive loss of function mutations in the DGKE gene cause TMA with histological features (increased deposition of mesangial matrix, thickening of the glomerular capillary walls, and splitting of the glomerular basement membrane) that resemble membrano-proliferative glomerulonephritis, but the mechanisms that lead to this disease are still unexplained (20, 31, 42). DGKs are intracellular lipid kinases devoted to phosphorylate diacylglycerol (DAG) to phosphatidic acid (36). At least 10 DGKs have been identified in mammals, differing mostly for the composition of the noncatalytic domains, which confer specific activity to each isoform (24). The epsilon isoform is a ubiquitous enzyme with higher level of expression in testis, cardiac and skeletal muscle, and kidney, where it has been demonstrated in podocytes and endothelial cells (20, 31). DGKε is constitutively active and has high specificity for DAG acylated with arachidonic acid (AA) in sn-2 position (sn-2-arachidonoyl-DAG). The high substrate selectivity, together with the constitutive activation of this enzyme, results in enrichment of the cellular polyphosphatidylinositides with AA acyl chains (25, 41). AA is the main precursor in the production of prostaglandins (PGs), and its cellular availability is the rate-limiting factor for the synthesis of prostanoids (19). PG synthesis is usually triggered by activation of membrane phospholipase A2 that releases AA from phospholipids in the cell membrane (19). Then the inducible enzyme PG endoperoxide synthase 2, also known as cyclooxygenase-2 (Cox-2), converts AA to the intermediate PG H2 (PGH2) that is, in turn, metabolized by specific PG synthases into PG E2 (PGE2), PG I2 (PGI2), thromboxane A2 (TxA2), PGF2α, and PGD2 (12). PGs are short-lived ubiquitous signaling molecules that are important mediators in kidney physiology and pathology and are required for microvascular angiogenesis and function (12, 34). Inactivation of Dgke in mice has been shown to affect recovery from seizures after brain electrogenic stimulation, but no glomerular phenotype has been described. Since mutations in humans result in TMA, we hypothesized that loss of Dgke in mice may cause subclinical glomerular lesions and may predispose to disease. Here we report that Dgke knockout mice have subclinical microscopic anomalies of the glomerular endothelium and basal membrane that worsen with age and develop extensive glomerular capillary occlusion when challenged with nephrotoxic serum (NS). We found that Dgke knockout mice fail to induce glomerular Cox-2 and the pro-angiogenic prostanoid PGE2 after puromycin aminonucleoside (PAN)-mediated glomerulonephritis. Concordantly, with the reduced expression of Cox-2, Dgke knockout mice were partially protected from developing podocyte foot process effacement and proteinuria after PAN injury. Dgke knockout mice also showed reduced expression of the antithrombotic cell adhesion molecule platelet endothelial cell molecule-1 (PECAM-1) in the glomerular endothelium. Notably, PGE2 supplementation was able to rescue motility defects of Dgke knockdown cells in vitro and to restore angiogenesis in an in vivo test. Our results suggest that Dgke has both endothelial and podocyte-specific functions, and that it is required for glomerular induction of Cox-2 and synthesis of vasoactive prostanoids.
MATERIALS AND METHODS
Mice knockouts.
Dgke knockout mice were developed on a C57/B6 background and have been previously described (36). All of the experiments were previously approved by the Institutional Animal Care and Use Committee of University of Texas Southwestern Medical Center.
NS and PAN-induced glomerulonephritis.
Glomerular basal membrane (GBM)-reactive NS was generated by Lampire Laboratories (Pipersville, PA), as previously described (43). Mice were challenged with intraperitoneal injections of complete Freund adjuvant, then with a first dose of NS (12.5 μg/g), followed by a second dose (5 μg/g) after 5 days. Equal amount of nonimmune isotypic serum (NIS) was used as a control. Fourteen days later, 24-h urine was collected, and kidneys were harvested for fixation or glomeruli isolation. PAN (Sigma, St. Louis, MO) was administered by intraperitoneal injection at the dose of 0.5 mg·g−1·day−1 for 2 days. An equal amount of volume per gram of body weight of saline was injected as a control. Mice were killed 3 or 10 days later, depending on the experiment. Kidneys were either fixed in 4% paraformaldehyde for histological analysis or snap frozen for immunofluorescence.
Transmission electron microscopy.
Samples were fixed/perfused with a 0.05% glutaraldehyde solution, embedded in Epon-812, cut in thin sections (600–900 nm), and stained with Reynolds lead citrate. Electron microscopy images were acquired under a Philips Tecnai-12 electron microscope (Philips, Eindhoven, The Netherlands).
Mouse glomeruli morphometric analysis.
Morphometric analysis of glomeruli of mice after NS and PAN-induced glomerulonephritis was performed using the software ImageJ [National Institutes of Health (NIH), Bethesda, MD; http://rsb.info.nih.gov/ij/]. Whole kidneys stained with hematoxylin and eosin (H&E) were imaged using Zeiss Axioscan Z1 microscope. Glomerular occlusion was determined by measuring the ratio of patent capillary area over total glomerular area examined. Electron microscopy images were used to quantify the extent of podocyte foot process effacement and the proportion of stressed endothelial cells. Podocyte foot process effacement was expressed as proportion of the length of basal membrane covered by two or more consecutive effaced foot processes over total linear length examined. Stressed endothelial cells (swollen cells with nuclei occluding more than 50% of the capillary lumen or with clear signs of endotheliosis) were manually detected in 20 consecutive capillary loops from multiple glomeruli. Results were expressed as proportion of stressed cells per number of examined capillary loops.
Immunofluorescence microscopy.
The following antibodies were used: Alexa Fluor 488 conjugate goat anti-rat IgG (Invitrogen, A-11006), C3 (Abcam, ab11862) PECAM-1/CD31 (BD Biosciences, 553930), fibrin (Dako, a0080), and WT-1 (Santa Cruz, sc-7385). After standard preparation, tissues were incubated overnight at 4°C in primary antibody and for 1 h at room temperature with the fluorescently labeled secondary antibody and mounted. Images were acquired using a Zeiss Axioplan 2 deconvolution microscope or a Zeiss LSM 510 confocal microscope.
Lentiviral infection, shRNA-mediated gene silencing.
Human umbilical vein epithelial cells (HUVECs) were obtained by American Type Culture Collection (Manassas, VA). DGKE and green fluorescent protein (GFP)-targeting short hairpin RNA (shRNA) lentiviral constructs were purchased by Open Biosystems (Lafayette, CO). The experiments were performed as previously described (21).
Wound-healing test for endothelial cell migration.
HUVECs were plated on glass-bottomed cells for 48 h to allow them to reach full confluence. A wound in the monolayer was then created by scratching the cells with a pipette tip, and images were taken 6 h later using a Zeiss LSM 510 microscope at four different points along the wound. Migration quantification was performed using the software ImageJ (NIH, Bethesda, MD; http://rsb.info.nih.gov/ij/) and was expressed as a percentage of the distance covered by migrating cells over the initial distance between the edges of the wound. PGE2 was purchased by Cayman Chemicals (Ann Arbor, MI) and was used at a final concentration of 3 μM.
In vivo angiogenesis assay.
The subcutaneous sponge model was used to determine the effects of prostanoids on in vivo angiogenesis (34). Sterile polyvinyl-acetal CF-50 round sponges (6-mm diameter, 50-μm pores, Medtronic Xomed) were implanted under the flank skin of wild-type and Dgke knockout mice (10 wk of age, 25 g body wt, n = 3 per treatment). The sponges were then injected on alternate days with 50 μl of either vehicle phosphate buffer saline (PBS) or PGE2 (10 μM). After 14 days, the sponges were isolated and snap frozen for immunofluorescence, which was performed on a Zeiss LSM 510 Meta Confocal Microscope. The area and the number of PECAM-1/CD31 positive structures were quantified by digital image analysis of 10 random images per sponge (total of 30 images per treatment group) using the software ImageJ (NIH, Bethesda, MD, http://rsb.info.nih.gov/ij/).
Macrophages isolation and culture.
Bone marrow macrophage precursors were isolated as described elsewhere (Nature Lipidomics Gateway, protocol ID: PP0000003500).
Isolation of mouse glomeruli.
Mice were perfused with 8 × 107 Dynabeds (Invitrogen, Carlsbad, CA) in 40 ml of Hanks' balanced salt solution. Kidneys were minced into 1-mm3 pieces and incubated with collagenase A (1 mg/ml) and DNAse I (1 U/ml) at 37°C for 30 min with gentle agitation. Collagenase-digested tissues were sequentially pressed through a cell strainer at 4°C, washed three times in Hanks' balanced salt solution, and collected with a Magnetic Particle Concentrator.
Quantitative real-time PCR.
Total RNA was isolated using TRIzol (Invitrogen, Carlsbad, CA) and purified with Qiagen RNeasy Mini Kit, according to the manufacturer's protocols. First-strand reverse transcription reactions were performed using the ThermoScript RT-PCR Kit (Invitrogen). Real-time PCR were performed using iQ SYBR Green Supermix (Bio-Rad). The β-actin gene was used as a normalizer.
Measurement of serum creatinine and blood urea nitrogen.
Serum creatinine concentrations were determined by capillary electrophoresis at the physiology core of O'Brien Center for Kidney Diseases in Dallas, TX. Blood urea nitrogen measurements were obtained using the Vitrops 250 chemistry analyzer.
Measurement of urinary albumin and creatinine.
Twenty-four-hour urine was collected using metabolic cages. Urinary albumin concentration was determined using the Albuwell microalbumin ELISA essay (Exocell, Philadelphia, PA). Urinary creatinine concentration was determined using a P/ACE MDQ Capillary Electrophoresis System and photodiode detector (Beckman-Coulter, Fullerton, CA) at 214 nm (44) in the physiology core of the O'Brien Center for Kidney Diseases in Dallas. Urinary albumin concentrations were normalized to the amount of excreted creatinine.
Measurement of urinary prostanoids.
Prostanoids were extracted by solid phase chromatography using octadecyl silica cartridges, resuspended in 25 μl of 70:30 methanol/water solution, and subjected to triple-quadruple (Waters, TQ-S) electrospray tandem mass spectrometry after adding an internal standard (Cayman Biochemicals, Ann Arbor, MI) for quantification. Urinary prostanoid concentrations were normalized to milligrams of excreted creatinine.
Statistical analysis.
Data analysis was performed using Excel (Microsoft) and Prism (version 5.03) software (GraphPad Software, San Diego, CA). Data are presented as means ± SE, unless otherwise specified. Two-tailed unpaired Student's t-test or nonparametric Mann-Whitney test were used to compare two groups of data.
RESULTS
Glomeruli of Dgke knockout mice have submicroscopic signs of endothelial impairment that become more pronounced with age.
Dgke knockout mice, which were previously generated to study the contribution of arachidonate signaling to epileptogenesis, are fertile and do not present any apparent phenotype (36). Dgke−/− light microscopy examination of H&E sections of Dgke knockout kidneys between 4 and 6 wk of age did not show significant differences, compared with wild-type littermates (Fig. 1A). Careful examination of transmission electron microscopy (TEM) images of Dgke knockout glomeruli, instead, evidenced modest signs of endothelial stress that were not detected in wild-type mice (Fig. 1, B and C): some endothelial cells in Dgke−/− glomeruli lost the normal fenestrated appearance and presented swelling of the endothelial rim. Segments of the GBMs were also abnormally inspissated or duplicated for the interposition of mesangial cells appendices, whereas the epithelial compartment was relatively well preserved, but no significant differences in albuminuria were detected between knockout and wild-type mice (Fig. 1D). The glomerular lesions became more severe in Dgke knockout mice at 1 yr of age: in H&E kidney sections, glomeruli had more frequently the typical “avascular” appearance, focal thickening of the capillary walls, and prominent endothelial cells nuclei (Fig. 1E). By TEM, signs of important endotheliosis, mesangial interposition, and splitting of the basal membrane were also evident (Fig. 1, F and G), recapitulating the glomerular human pathology of subjects with DGKE loss of function mutations. Urinary albumin tended to be higher in Dgke knockout mice compared with wild-type controls (Fig. 1H).
Fig. 1.
Glomeruli of diacylglycerol kinase-ε (Dgke) knockout (KO) mice have submicroscopic signs of endothelial impairment that worsen with age. A: representative light microscopy images of Dgke KO mice glomeruli compared with wild-type (WT) littermates at 6 wk of age. Dgke KO glomeruli are apparently normal and indistinguishable from WT controls. Hematoxylin and eosin (H&E), scale bars = 20 μm. B: on transmission electron microscopy (TEM), in the glomeruli of Dgke KOs, some capillaries show modest signs of endothelial stress with loss of fenestrae and swelling of the endothelial rim (black arrowheads; left). Segments of the glomerular basal membranes (GBMs) appear inspissated (black arrow, left) or duplicated for the interposition of appendices of mesangial cells (white arrows, left and inset). The epithelial compartment is relatively well preserved, and only minimal podocyte foot process effacement is observed (white arrowheads, left and inset). Notice the presence of fenestrae (black arrowheads, right) and the normal foot processes (white arrowheads, right and inset) in a WT littermate. Scale bars = 5 μm. Insets show boxed areas at higher magnification. C: quantification of the number of stressed endothelial cells per number of capillary loops examined. Values are means ± SE; n = 20 consecutive capillary loops form multiple glomeruli, with 2 mice per experimental group. D: urinary albumin-to-creatinine ratio (ACR) in 24-h urine of Dgke KO and WT mice. Values are means ± SE; n = 3 mice per group. ns, Nonsignificant. E: light microscopy images of Dgke KO mice glomeruli compared with WT littermates at 1 yr of age. Glomerular congestion and focal capillary obliteration (arrows) with thickening of the GBM (arrowheads) are detectable in some glomeruli of Dgke KOs compared with WT controls. Scale bars = 20 μm. Insets show boxed areas at higher magnification. F: TEM images of Dgke KO mice glomeruli compared with WT littermates at 1 yr of age. Swelling of the endothelial rim (black arrowheads) is frequently accompanied by mesangial interposition (white asterisks) and splitting of the basal membrane (white arrowhead), which are indicative of chronic glomerular repair. Scale bars = 1 μm. G: quantification of the number of stressed endothelial cells per number of capillary loops examined. Values are means ± SE; n = 20 consecutive capillary loops form multiple glomeruli, with 2 mice per experimental group. H: urinary ACR in 24-h urine of Dgke KO and WT mice. Values are means ± SE; n = 3 WT and 3 Dgke−/− mice. P values were calculated by Student's t-test.
Dgke knockout mice are more susceptible to glomerular injury when challenged with NS.
To determine if Dgke knockouts were more exposed of wild-type mice to develop acute phenotype at younger age, we used an experimental model of immune-mediated glomerulonephritis, challenging the mice with NS (10, 43). To this purpose, we injected 4-wk-old Dgke knockouts and wild-type littermates with Freund's adjuvant, followed, after 5 days, by the injection of subtoxic doses of NS or NIS as a control. The mice were killed 14 days later, and kidneys were examined by light and electron microscopy. H&E sections of kidneys of Dgke knockout mice that received NS had evident signs of microvascular congestion: capillary loops, were partially or completely obliterated, and trapped erythrocytes were frequently observed. Hypercellularity and mesangial expansion were also evident (Fig. 2, A, top left, and B). Oppositely, Dgke+/+ mice challenged with NS (Fig. 2, A, top right, and B) and Dgke knockout mice that received NIS (Fig. 2, A, top middle, and B) appeared mostly normal, showing normocellular glomeruli and patent capillary tufts. Similarly, TEM of glomeruli of Dgke−/− mice treated with NS (Fig. 2, C, left, and F) presented mesangial expansion and infiltration of the GBM, loss of endothelial fenestrae, diffuse swelling of the endothelial cells that partially obliterated the capillary lumens, and trapped erythrocytes. Instead, capillary loops of Dgke knockout mice treated with NIS and of wild-type littermates' glomeruli after NS (Fig. 2, C, center and right, and F) were patent with clearly detectable endothelial fenestrations. Dgke knockout mice had higher levels of urinary albumin (Fig. 3A) and more diffuse foot process effacement (Fig. 3B) 14 days after NS injection, suggesting impaired repairing capacity after immune-mediated glomerular injury. No significant differences were detected in the number of glomerular podocytes (Fig. 3, C and D) and in serum hemoglobin, red blood cells, and platelet counts among all of the experimental groups (Fig. 3E). On immunofluorescence microscopy, glomeruli of Dgke knockout mice treated with NS were more often positive for complement C3 (Fig. 3, F and G) and expressed less anti-thrombotic PECAM-1 (CD31 in the figures, Fig. 3, H and I), compared with wild-type NS-treated controls. These data indicate that lack of Dgke predisposes to extensive glomerular capillary occlusion after immunomediated glomerular injury.
Fig. 2.
Dgke KO mice develop glomerular thrombotic microangiopathy when injected with nephrotoxic serum (NS). A: representative images of Dgke KO mice glomeruli (left) after injection of subtoxic doses of rabbit NS compared with WT littermates (right). Glomeruli of KO mice show increased mesangial matrix (arrowheads), diffuse congestion of the capillary loops (black arrow), and numerous entrapped erythrocytes (white arrow). Capillary obliteration is not detectable in WT littermates (right) after injection of the same dose of NS (arrows indicate patent capillary loops) and in Dgke KOs treated with nonimmune isotypic serum (NIS; center). H&E staining, scale bars = 20 μm. Bottom: immunofluorescence microscopy images of glomeruli of the same mice probed with an antibody against rabbit IgG (rIgG), showing that the animals received comparable amount of NS or no NS in the NIS control. Mice were 6 wk of age at the date of the experiment. Scale bars = 20 μm. B: quantification of the average patent capillary area in glomeruli of WT and Dgke KO mice after injection of NS or of isotypic NIS as a control, obtained by digital image analysis. Values are means ± SE; n = 2 mice per group, with 10 optical fields per mouse. P values were calculated by Student's t-test. C: TEM images of Dgke KO after NS or isotypic NIS injections and WT littermate glomeruli after NS injection. In kidneys of Dgke KOs after NS injection (left) mesangial cells (m) are focally increased in number and infiltrate segments of the GBM (white asterisk). Endothelial cells (black asterisks) are swollen, and capillary rims are irregular and lack the typical fenestrations (black arrows). Lumens are partially obliterated by swollen endothelium and trapped irregular-shaped erythrocytes (stars). Notice that podocytes' foot processes (black arrowhead and inset) are relatively well conserved. Capillary loops of Dgke KOs treated with NIS and of WT littermates after NS injections (stars; middle and right) are patent, endothelial fenestrations are clearly detectable (arrows and insets), and podocytes' foot processes appear normal (arrowhead). Scale bars = 10 μm. D and E: TEM images at higher magnification of Dgke KO glomeruli after injection of NS that show bulky endothelial cells (black asterisks) with almost completely obstructed capillary lumens and the interposition of a mesangial cell (E; white asterisk), which results in the splitting of the basal membrane (E; black arrowheads). Scale bars = 2 μm. F: quantification of the number of stressed endothelial cells per number of capillary loops in glomeruli of Dgke KO and WT mice 14 days after injection with NS. Values are means ± SE; n = 20 consecutive capillary loops form multiple glomeruli, with 2 mice per experimental group.
Fig. 3.
Morphometric and functional analysis of Dgke KO mice after NS injury. A: albumin concentrations in 24-h urine collected from Dgke KO and WT mice in basal conditions and at 7 and 14 days after injection with NS or NIS, a control. Values are means ± SE. n = 3 WT and 3 Dgke KO mice per group. P values were calculated by Student's t-test. B: average length of podocyte effacement calculated by digital image analysis of TEM images. Values are means ± SD; n = 10 images per mouse, with 2 mice per experimental group. P values were calculated by Student's t-test. Immunofluorescence microscopy images (C) and quantification (D) of the number of WT-1-positive podocytes per glomerulus in the four experimental groups are shown. Values are means ± SD; n = 3 mice per group. E: serum hemoglobin (Hb), red blood cells (RBC), and platelet (PLT) count in Dgke KO and WT mice in basal conditions and at 14 days after injection with NS or NIS, a control. No significant difference among these parameters was detected. Values are means ± SD; n = 3 mice per group. P values were ns, calculated by Student's t-test. F: representative immunofluorescence microscopy images Dgke KO mice glomeruli (left) after NS injection compared with WT littermates (right), using an antibody against the complement C3. G: quantification of the number of glomeruli positive for C3 deposition. Values are means ± SE; n = 2 mice per group, with 20 glomeruli per mouse. P values were calculated by Student's t-test. H and I: representative immunofluorescence microscopy images (H) and digital quantification (I) of glomerular CD31 expression in Dgke KO kidneys and WT mice 14 days after treatment with NS or with NIS as a control. Veh, vehicle.
Dgke knockout mice are resistant to PAN-induced glomerulonephritis.
The model of immune-mediated nephritis used in the previous experiment is based on complement activation that is triggered by the deposition of antibodies raised against GBM antigens. To test if Dgke knockout mice are more susceptible also to IgG/complement-independent glomerular injury, we treated mice with PAN, a drug with selective podocyte toxicity that induces self-limited damage, independent from complement activation (16). Dgke knockouts and wild-type littermates between 8 and 10 wk of age were injected with PAN (0.5 mg·g−1·day−1 for 2 days), and kidney histology was evaluated after 3 days, when the highest acute PAN toxicity has been reported (2), and 10 days, to monitor recovery from injury. By light microscopy of H&E-stained kidney sections, we observed congestion in some glomeruli of Dgke knockout and wild-type mice treated with PAN (Fig. 4A), but no statistically significant difference was detected between these two groups (Fig. 4B, 150 glomeruli examined, 50 random chosen glomeruli per mouse, 3 mice per group). In TEM images (Fig. 4C), some glomeruli of knockout and wild-type mice treated with PAN showed signs of mild endothelial stress (swollen endothelial cells with enlarged nuclei, absence of capillary fenestrations, and blebs of the endothelial rim), whereas podocytes' foot processes were often well conserved. Conversely, podocytes' foot processes in wild-type mice treated with PAN were extensively effaced, as shown by morphometric analysis of foot process effacement of TEM images (Fig. 4D, 10 glomeruli per mouse, n = 4 mice per group). Consistent with this finding, urinary albumin-to-creatinine ratios from 24-h urine collections were lower in Dgke knockouts after PAN injection compared with wild-type controls 3 days after treatment, and recovered faster by day 10 (Fig. 4E). No differences in the number of podocytes were detected between the experimental groups (Fig. 4F). By immunofluorescence microscopy, we detected complement C3 in a single glomerulus in one Dgke knockout (Fig. 4G, arrow) but never in wild-type mice (50 glomeruli counted per mouse, n = 3 mice per group). We conclude that, at the used doses, PAN induces mild endotheliosis in both Dgke knockout and wild-type mice, and that Dgke knockout podocytes are more resistant to PAN injury compared with wild-type controls.
Fig. 4.
Puromycin aminonucleoside (PAN)-induced glomerulonephritis in Dgke KO mice promotes glomerular endothelial lesions in the absence of significant complement activation. A: light microscopy images of Dgke KO mice glomeruli (left) and WT littermate (right) 3 days after PAN injections. The capillary spaces in some glomeruli of both Dgke KO and WT mice after PAN injection are occluded. B: quantification of the average patent capillary area in glomeruli of WT and Dgke KO mice after PAN injection, obtained by digital image analysis. Values are means ± SD; n = 3 mice per group, with 10 optical fields per mouse. P values were calculated by Student's t-test. C: TEM images of a glomerulus of a Dgke KO mouse (left) and a WT littermate (right) 3 days after PAN injection. Some endothelial cells are swollen and have enlarged nuclei (white asterisk), and some capillaries present loss of endothelial fenestrations (black arrow). Podocytes' foot processes are often conserved in Dgke KO mice treated with PAN (left; arrowheads) and more extensively effaced in WT mice treated with PAN (right; arrowheads). Scale bars = 5 μm. D: average length of podocyte effacement calculated by digital image analysis of TEM images. Values are means ± SD; n = 10 images per mouse, with 4 mice per experimental group. P values were calculated by Student's t-test. E: 24-h urinary ACR of Dgke−/− and WT mice treated with PAN or Veh as a control. Dgke KO mice are partially protected from developing acute proteinuria and recover faster after PAN treatment, compared with WT controls. Values are means ± SD; n = 4 mice per experimental group. P values were calculated by Student's t-test. F: quantification of the number of podocytes per glomerulus in the 4 experimental groups, obtained by morphological analysis of TEM images. Values are means ± SD; n = 5 glomeruli per mouse, with 3 mice per group. P values were calculated by Student's t-test. G: immunofluorescence microscopy images of complement C3 deposition in glomeruli of Dgke KO mice and WT controls 10 days after PAN injection. Glomeruli are highlighted by a dashed line. One single glomerulus was positive in a Dgke KO mouse (arrow). n = 50 glomeruli counted per mouse, 3 mice per group. Scale bars = 100 μm.
Dgke is required for the expression of the inducible enzyme Cox-2 in normal glomeruli.
Cox-2 is a ubiquitous enzyme required for a rate-limiting reaction in the synthesis of PGs from AA. Unlike the cognate enzyme Cox-1 that is constitutively active, Cox-2 is an inducible enzyme (33, 38). In the kidney, Cox-2 is expressed in glomeruli, thick ascending limb of Henle, and in medullary interstitial cells (14). Importantly, Cox-2 is expressed by podocytes, and it is required for correct glomerular homeostasis (3, 13): both increased and decreased Cox-2 expression in mouse podocytes, in fact, result in different forms of glomerular disease, indicating that a balanced activity of this enzyme is necessary for correct glomerular development and maintenance (3). Microarray expression analysis of mouse brains after electrical shock had previously revealed that Dgke knockouts failed to induce transcription of Cox-2 compared with wild-type controls (22). We tested if Cox-2 expression after stress was also compromised in other tissues and more specifically in kidneys. Since Cox-2 expression is induced in macrophages (39) and fibroblasts (5) when stimulated with lipopolysaccharide (LPS) and with interleukin 1β (IL-1β), respectively, we measured by quantitative real-time PCR the levels of Cox-2 mRNA in Dgke−/− and wild-type bone marrow-derived macrophage precursors, 12 h after stimulation with LPS (4 ng/ml) and in skin primary fibroblasts cultured for 4 h in medium supplemented with IL-1β (2 ng/μl). We found that expression of Cox-2 was upregulated after exposure to LPS in wild-type bone marrow-derived macrophage precursors (Fig. 5A), but not in Dgke−/− cells, and in wild-type, but not in knockout fibroblasts, exposed to IL-1β (Fig. 5B). Western blots of fibroblasts extracts confirmed the impaired expression of Cox-2 in Dgke null cells, both in basal conditions and after IL-1β stimulation (Fig. 5C). No changes in Cox-1 expression in wild-type and knockout fibroblasts were detected by quantitative real-time PCR and Western blot (not shown). Then we asked if Cox-2 induction is also compromised in Dgke knockout kidneys. We examined by quantitative real-time PCR and by Western blot cortex extracts 3 days after injections with PAN or vehicle-injected controls. Cox-2 transcripts were similar in Dgke knockouts and in wild-type littermates, but failed to be upregulated after PAN injection (Fig. 5D). Similarly, Cox-2 protein levels were reduced in cortexes from Dgke knockout mice after PAN injection compared with wild-type littermates (Fig. 5E). Importantly, Cox-2 expression was also impaired in Dgke−/− isolated glomeruli (Fig. 5F). The lower expression levels of Cox-2 in Dgke null glomeruli compared with wild type is consistent with the reduced proteinuria and podocytes foot process effacement observed in Dgke knockout mice, in agreement with the detrimental effect of Cox-2 on these parameters (3, 4, 40).
Fig. 5.
Cyclooxygenase-2 (Cox-2) induction is impaired in Dgke null cells. A: quantification of Cox-2 expression, measured by real-time PCR, in bone marrow-derived macrophage (MΦ) precursors, isolated from Dgke KO mice and WT littermates and exposed to LPS or Veh as a control. Cox-2 expression is induced by stimulation with LPS in MΦ isolated from WT but not from Dgke KOs (n = 6 mice per group). AU, arbitrary units. Values are means ± SE. P values were calculated by Student's t-test. B: quantification by real-time PCR of Dgke KO and WT skin fibroblasts stimulated with IL-1β. Cox-2 expression is decreased in mutant fibroblasts and fails to be induced after IL-1β stimulation. Values are means ± SE; n = 4 mice per group. P values were calculated by Student's t-test. C: Western blot of Dgke KO and WT fibroblast lysates exposed to IL-1β or Veh as a control, probed with an antibody against Cox-2. Two replicates were loaded for each experimental condition. Cox-2 was undetectable in Dgke KO fibroblasts before and after stimulation with IL-1β, but was abundantly expressed in WT cells. For two WT samples (column 3 and 4 from left), one-half of the amount of protein was loaded to show the increase of Cox-2 expression after exposure to IL-1β. D: quantification by real-time PCR of the transcripts of Cox-2 in kidney cortexes of Dgke KO mice and WT littermates, 3 days after the injection of PAN or Veh as a control. Cox-2 expression in Dgke KO cortexes is increased in PAN-treated WT mice, but not in Dgke KOs. Values are means ± SE; n = 4 mice per group. P values were calculated by Student's t-test. E: Western blot showing the amount of Cox-2 in in kidney cortexes of Dgke KO mice and WT controls, 3 days after treatment with PAN or Veh as a control. Cox-2 is increased in cortexes of PAN-treated WT mice, but not in Dgke KOs. F: quantification by real-time PCR of Cox-2 expression in isolated glomeruli from Dgke KO mice and WT littermates, 3 days after the injection of PAN or Veh as a control. Cox-2 expression in Dgke KO glomeruli is induced in PAN-treated WT mice, but not in Dgke KOs. Values are means ± SE; n = 4 mice per group. P values were calculated by Student's t-test.
Lack of Dgke affects prostanoid synthesis in mouse kidneys.
Cox-2 and the cognate enzyme Cox-1 catalyze the formation of the cyclic endoperoxides PGG2 and PGH2, which are obligate intermediates for the synthesis of prostanoids. Although Cox-2 and Cox-1 potentially act on the same substrate, they have a different affinity for AA and are functionally coupled with different prostanoid synthases (27). As a consequence, PGE2 and PGF2 synthesis in the kidney is mostly dependent on Cox-2 activity (33). PGE2 is the most abundant prostanoid in the kidney and has multiple effects on the glomerular circulation, acting as a vasodilator of the afferent arteriole and modulating the constrictor effect of angiotensin II on mesangial cells (7, 37). PGE2 is also capable to promote proliferation and migration of HUVEC cells in vitro and to sustain angiogenesis in vivo (28, 34). For this reason, we measured the levels of PGE2 and PGF2α in the urine of Dgke−/− mice and wild-type littermates, 3 days after PAN injection, by liquid chromatography-electrospray tandem mass spectrometry (23). Concordant with Cox-2 expression, the urinary excretion of these two Cox-2 enzymatic products was reduced in Dgke−/− mice compared with wild-type controls after PAN injection (Fig. 6), indicating impaired induction of prostanoid synthesis in Dgke null mice after podocyte stress. Twenty-four-hour urinary 11-dehydrothromboxane B2, the degradation product of TxA2, was also lower in knockout mice after PAN injection compared with the wild type, although the difference did not reach statistical significance.
Fig. 6.
Lack of Dgke affects prostanoids synthesis in mouse kidneys. Urinary concentrations of prostaglandins (PG) E2 (A), PGF2 (B), and 11-dehydrothromboxane B2 (11-dh-TxB2; C) in 24-h urine of Dgke KOs and WT controls in basal conditions and 3 days after PAN injection or Veh as a control, determined by liquid chromatography-electrospray tandem mass spectrometry. Excretion is significantly lower in Dgke KOs compared with controls after PAN treatment. Box and whiskers are 25th and 75th and minimum and maximum, respectively. Lines represent medians; dots correspond to means. Values are means ± SE; n = 4 samples per group. P values were calculated with the Mann-Whitney rank sum t-test. uCr, urinary creatinine.
Dgke knockout endothelial cells present defects that improve with PGE2 supplementation.
Recently, loss of Dgke has been associated with impaired motility and angiogenesis, distress of endothelial cells, and increased apoptosis in vitro, suggesting a cell-autonomous endothelial function of Dgke (1). Given the important pro-angiogenic effect of PGE2 on endothelial cells (1, 34), we hypothesized that impaired PGE2 production in Dgke knockout mice may concur to the endothelial stress observed in the absence of Dgke. Activated endothelial cells express more pro-thrombotic factors, such as intercellular adhesion molecule-1 and tissue factor, and less anti-thrombotic molecules, such as PECAM-1. PECAM-1 is a cell-cell junction protein that is important for normal angiogenesis (6) and is known to inhibit thrombus formation in vivo (8). To test the expression of this protein in Dgke knockout glomeruli, we probed wild-type and Dgke knockout kidneys treated either with PAN or vehicle, with an antibody against PECAM-1. Digital analysis of immunofluorescence microscopy images showed that glomeruli of knockout mice after PAN had reduced PECAM-1 expression, compared with wild-type mice (Fig. 7, A and B). Expression of PECAM-1 was also impaired in cortexes of Dgke knockout mice in basal conditions and 3 days after PAN injection, as detected by quantitative real-time PCR (Fig. 7C). To verify if PGE2 may affect PECAM-1 expression in Dgke defective endothelial cells, we silenced DGKE in HUVEC cells by shRNA and estimated the amount of PECAM-1 by Western blot after exposing these cells to PGE2 for 4 h. We found that PECAM-1 protein levels were lower in HUVEC cells after DGKE silencing compared with the GFP-silenced controls. The amount of PECAM-1 increased, though, after exposing HUVECs to PGE2-supplemented medium, indicating that PGE2 is required to induce PECAM expression in HUVECs (Fig. 7D). We asked, then, if PGE2 supplementation could also improve the migration defects presented by the DGKE knockdown HUVECs in vitro (1). To this purpose, we assayed the effect of PGE2 on migratory ability of DGKE knockdown HUVEC cells in a wound-healing assay in vitro, by measuring the migration of DGKE knockdown cells on a coverslip after scratching the cell monolayer with a pipette tip. The distance covered by migrating cells after wounding was lower in DGKE knockdown cells compared with GFP-targeted controls, as previously described (1), but improved with PGE2 supplementation (Fig. 7, E and F). Finally, to explore if PGE2 supplementation may affect endothelial angiogenesis also in vivo, we performed experiments of angiogenesis in subcutaneous sponge implants (1, 32). Sterile polyvinyl-acetal sponges were implanted under the flank skin of Dgke knockout mice and of wild-type littermates (8–12 wk of age, n = 4 mice) and were injected with PGE2 or with equal volume of PBS, on alternate days for 14 days. After this time, mice were killed, and sponges were collected, fixed with paraformaldehyde, and probed with an antibody against PECAM-1. Images were taken by immunofluorescence confocal microscopy, and the extent of PECAM-1-positive surface or the number of positive neovascularized structures per random microscopy field was quantified by digital image analysis. We found that sponges implanted in Dgke knockout mice had reduced PECAM-1-positive structures and reduced average PECAM-1-positive surface per neovascularized structure, compared with sponges implanted in wild-type littermates (Fig. 7, G–I, n = 2 sponges per mouse in each group, 4 mice per group). Importantly, expression of PECAM-1 increased in sponges injected with PGE2, suggesting that the defective angiogenic potential of Dgke null endothelial cells may be partially reversed by PGE2.
Fig. 7.
Dgke KO mice have endothelial defects that improve with PGE2 supplementation. A and B: representative immunofluorescence microscopy images (A) and quantification by digital image analysis (B) of glomerular CD31 expression in Dgke KO kidneys and WT mice 3 days after treatment with PAN or with PBS as a control. CD31 signal was lower in Dgke KOs compared with controls. Glomeruli are highlighted by dotted lines. Scale bars = 50 μm. Quantification data are expressed as average ± SD (n = 3 mice, 10 optical fields per mouse). C: expression of CD31 in cortexes of Dgke KO and WT mice, 3 days after treatment with PAN or with PBS as a control, measured by quantitative real-time PCR. Values are means ± SE from triplicate samples. P values were calculated by Student's t-test. D: Western blot of human umbilical vein epithelial cell (HUVEC) lysates after short hairpin RNA (shRNA)-mediated silencing of DGKE (sh-Dgke) compared with control cells infected with a green fluorescent protein (GFP)-targeting shRNA (sh-GFP). CD31 is lower in DGKE-silenced HUVECs compared with the controls and increases after 4-h exposure to PGE2 supplemented medium. E: representative differential interference contrast microscopy images of DGKE knockdown and GFP-targeted control HUVECs immediately after wounding the cell monolayers (0 h) and 6 h after exposure to PGE2-supplemented medium or to Veh-supplemented medium, as a control. Dashed lines were overlaid to the images to mark the border of the wound. F: quantification by digital image analysis of the distance covered by endothelial cells migrated from the border of the wound 5 h after exposure to PGE2 supplemented medium, expressed as the ratio between covered distance and total width of the wound. Data from triplicate experiments are expressed as average ± SE. P values were calculated by Student's t-test. G: representative immunofluorescence confocal microscopy images of polyvinyl-acetal sponges implanted subcutaneously in Dgke KO mice (8–12 wk of age, n = 4 sponges per mouse, 4 mice) and of WT littermates injected with PGE2 or with equal volume of Veh on alternate days for 14 days, probed with an antibody against CD31. Scale bars = 20 μm. H and I: quantification by digital image analysis of the number of positive neovascularized structures, expressed as average of CD3-immunoreactive area of CD31-positive structures (H), or as number of CD31-positive structures per random microscopy field (I). Data were obtained analyzing 10 random images per sponge and are expressed as average ± SD; n = 4 sponges per mouse, with 4 mice per each experimental group. P values were calculated by Student's t-test.
DISCUSSION
In the present work, we have characterized the glomerular phenotype of Dgke knockout mice and investigated possible mechanisms of disease promoted by lack of Dgke. Dgke−/− mice are more resistant than wild type to develop seizures after brain electrical stimulation, but no apparent kidney phenotype has been so far reported (36). Here we have shown that, although Dgke null mice do not have spontaneous clinical signs of kidney disease and have normal serum creatinine and urinary albumin, they present microscopic glomerular lesions (endotheliosis and mesangial interposition of the GBM) that worsen with age, and that they are more susceptible to develop overt glomerular congestion after NS injury. We also tested the susceptibility of Dgke knockout mice to immuno-independent glomerular injury by administering PAN, a drug with selective podocyte toxicity (16). Administration of PAN was associated with signs of endothelial stress in glomeruli of both Dgke knockout and wild-type mice, suggesting that these lesions are secondary to podocyte injury. We did not detect significant glomerular deposition of complement C3 between Dgke knockout and wild-type mice, at the used PAN dosage. Unfortunately, we were not able to perform the experiment with higher dosage or prolonged exposure to PAN, because of the high mouse mortality that we observed in these experimental conditions. However, after NS-induced nephritis, we noticed that more glomeruli were positive for complement C3 in Dgke knockout mice compared with controls. In the attempt to reconcile these evidences, we can speculate that complement activation is not the initial determinant of the phenotype in Dgke knockouts, but Dgke null endothelial cells may be more susceptible to fix the complement secondarily, because they are more susceptible to injury and death. This hypothesis is compatible with the recent report that DGKE knockdown HUVEC cells have an increased tendency to apoptosis and decreased expression of two cell surface regulators of the complement activation, the complement inhibitor membrane cofactor protein and the decay accelerating factor (1). The authors of this paper, though, failed to detect complement deposition on these cells in a test in vitro, and, therefore, more targeted in vivo studies will be required to clarify this point. Another question that will need to be addressed, which will require the use of tissue-specific Dgke knockouts, is if endothelial cells, podocytes, or both contribute to determine the glomerular lesions in the absence of Dgke. The effect of DGKE small interfering RNA-mediated silencing on HUVEC cell survival and angiogenic potential indicates cell-autonomous functions of Dgke in the endothelium. On the other hand, the impaired Cox-2 expression after stress in all of the cell lines and tissues that we have examined, including kidney glomeruli, infers that Dgke is required for Cox-2 induction also in podocytes, which is the principal glomerular source of Cox-2 (18), and may affect the defective endothelium in a cell nonautonomous fashion, through impaired production of PGE2. This hypothesis is corroborated by our in vitro and in vivo experiments that show improved angiogenic potential and PECAM-1 expression of DGKE knockdown HUVEC cells after PGE2 supplementation. The resistance of Dgke null podocytes to PAN injury, in fact, argues that the reduced Cox-2 expression in Dgke null glomeruli is not secondary to loss of podocytes. Finally, the mechanisms by which Dgke controls Cox-2 induction will also need to be investigated. Dgkε is required to maintain the phospholipids acyl composition of the cell membranes, and thus is likely to affect multiple downstream signaling pathways. If and how any of these pathways may regulate Cox-2 expression will need to be experimentally proved. In summary, we have reported that Dgke knockout mice have glomerular pathology that reproduces the lesions observed in patients with biallelic loss of function mutations in DGKE. Our studies also show that the lipid kinase Dgkε is required for the maintenance of the glomerular endothelium and participates in the regulation of the expression of Cox-2 and the production of PGE2 in normal glomeruli.
GRANTS
M. Attanasio was supported by the National Institutes of Health (NIH) (1R01DK090326-01A1, P30DK079328-04), the Satellite Healthcare, Norman S. Coplon Extramural Research Grant, and the ASN Norman Siegel Research Award. F. Ozaltin is supported by the European Community's Seventh Framework Programme (FP7/2007-2013) (EURenOmics; Grant 2012-305608). The Nephrogenetics Laboratory at Hacettepe University was established by the Hacettepe University Infrastructure Project (Grant 06A101008). K. Topham was supported by NIH grant CA095463.
DISCLOSURES
No conflicts of interest, financial or otherwise, are declared by the author(s).
AUTHOR CONTRIBUTIONS
Author contributions: J.Z., M.C., D.L., C.R., S.-S.W., A.A.R., B.L., S.Z., B.J., Y.D., K.V., H.W., S.E., R.J.Q., M.K.T., C.M., F.O., D.K.M., N.G.B., and M.A. performed experiments; J.Z., M.C., D.L., S.-S.W., A.A.R., B.L., X.J.Z., N.G.B., and M.A. analyzed data; J.Z., M.C., D.L., and M.A. interpreted results of experiments; J.Z., M.C., D.L., and M.A. edited and revised manuscript; J.Z., M.C., D.L., A.A.R., B.L., and M.A. approved final version of manuscript; D.L. and M.A. drafted manuscript; M.A. conception and design of research; M.A. prepared figures.
ACKNOWLEDGMENTS
We thank Patricia Cobo-Stark and Jessica Lucas for technical support, and Rafael Rodriguez from Medtronic Xomed for kindly providing the CF50 polyvinyl sponges.
REFERENCES
- 1.Bruneau S, Neel M, Roumenina LT, Frimat M, Laurent L, Fremeaux-Bacchi V, Fakhouri F. Loss of DGKepsilon induces endothelial cell activation and death independently of complement activation. Blood 125: 1038–1046, 2015. [DOI] [PubMed] [Google Scholar]
- 2.Chen A, Wei CH, Sheu LF, Ding SL, Lee WH. Induction of proteinuria by adriamycin or bovine serum albumin in the mouse. Nephron 69: 293–300, 1995. [DOI] [PubMed] [Google Scholar]
- 3.Cheng H, Fan X, Guan Y, Moeckel GW, Zent R, Harris RC. Distinct roles for basal and induced COX-2 in podocyte injury. J Am Soc Nephrol 20: 1953–1962, 2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Cheng H, Wang S, Jo YI, Hao CM, Zhang M, Fan X, Kennedy C, Breyer MD, Moeckel GW, Harris RC. Overexpression of cyclooxygenase-2 predisposes to podocyte injury. J Am Soc Nephrol 18: 551–559, 2007. [DOI] [PubMed] [Google Scholar]
- 5.Cruz-Gervis R, Stecenko AA, Dworski R, Lane KB, Loyd JE, Pierson R, King G, Brigham KL. Altered prostanoid production by fibroblasts cultured from the lungs of human subjects with idiopathic pulmonary fibrosis. Respir Res 3: 17, 2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.DeLisser HM, Christofidou-Solomidou M, Strieter RM, Burdick MD, Robinson CS, Wexler RS, Kerr JS, Garlanda C, Merwin JR, Madri JA, Albelda SM. Involvement of endothelial PECAM-1/CD31 in angiogenesis. Am J Pathol 151: 671–677, 1997. [PMC free article] [PubMed] [Google Scholar]
- 7.Edwards RM. Effects of prostaglandins on vasoconstrictor action in isolated renal arterioles. Am J Physiol Renal Fluid Electrolyte Physiol 248: F779–F784, 1985. [DOI] [PubMed] [Google Scholar]
- 8.Falati S, Patil S, Gross PL, Stapleton M, Merrill-Skoloff G, Barrett NE, Pixton KL, Weiler H, Cooley B, Newman DK, Newman PJ, Furie BC, Furie B, Gibbins JM. Platelet PECAM-1 inhibits thrombus formation in vivo. Blood 107: 535–541, 2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Fremeaux-Bacchi V, Miller EC, Liszewski MK, Strain L, Blouin J, Brown AL, Moghal N, Kaplan BS, Weiss RA, Lhotta K, Kapur G, Mattoo T, Nivet H, Wong W, Gie S, Hurault de Ligny B, Fischbach M, Gupta R, Hauhart R, Meunier V, Loirat C, Dragon-Durey MA, Fridman WH, Janssen BJ, Goodship TH, Atkinson JP. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 112: 4948–4952, 2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Fu Y, Du Y, Mohan C. Experimental anti-GBM disease as a tool for studying spontaneous lupus nephritis. Clin Immunol 124: 109–118, 2007. [DOI] [PubMed] [Google Scholar]
- 11.George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med 371: 654–666, 2014. [DOI] [PubMed] [Google Scholar]
- 12.Hao CM, Breyer MD. Physiological regulation of prostaglandins in the kidney. Annu Rev Physiol 70: 357–377, 2008. [DOI] [PubMed] [Google Scholar]
- 13.Harris RC, Breyer MD. Physiological regulation of cyclooxygenase-2 in the kidney. Am J Physiol Renal Physiol 281: F1–F11, 2001. [DOI] [PubMed] [Google Scholar]
- 14.Harris RC, Mckanna JA, Homma T, Jacobson HR, Dubois RN, Breyer MD. Cycloxygenase-2 is localized to the macula densa and papillary interstitial-cells and increases with salt restriction. J Am Soc Nephrol 5: 680–680, 1994. [Google Scholar]
- 15.Hosler GA, Cusumano AM, Hutchins GM. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. Arch Pathol Lab Med 127: 834–839, 2003. [DOI] [PubMed] [Google Scholar]
- 16.Jo YI, Cheng H, Wang S, Moeckel GW, Harris RC. Puromycin induces reversible proteinuric injury in transgenic mice expressing cyclooxygenase-2 in podocytes. Nephron Exp Nephrol 107: e87–e94, 2007. [DOI] [PubMed] [Google Scholar]
- 17.Keir L, Coward RJ. Advances in our understanding of the pathogenesis of glomerular thrombotic microangiopathy. Pediatr Nephrol 26: 523–533, 2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Komhoff M, Grone HJ, Klein T, Seyberth HW, Nusing RM. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am J Physiol Renal Physiol 272: F460–F468, 1997. [DOI] [PubMed] [Google Scholar]
- 19.Kunze H, Vogt W. Significance of phospholipase A for prostaglandin formation. Ann N Y Acad Sci 180: 123–125, 1971. [DOI] [PubMed] [Google Scholar]
- 20.Lemaire M, Fremeaux-Bacchi V, Schaefer F, Choi MR, Tang WH, Le Quintrec M, Fakhouri F, Taque S, Nobili F, Martinez F, Ji WZ, Overton JD, Mane SM, Nurnberg G, Altmuller J, Thiele H, Morin D, Deschenes G, Baudouin V, Llanas B, Collard L, Majid MA, Simkova E, Nurnberg P, Rioux-Leclerc N, Moeckel GW, Gubler MC, Hwa J, Loirat C, Lifton RP. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet 45: 531–536, 2013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Li B, Rauhauser AA, Dai J, Sakthivel R, Igarashi P, Jetten AM, Attanasio M. Increased hedgehog signaling in postnatal kidney results in aberrant activation of nephron developmental programs. Hum Mol Genet 20: 4155–4166, 2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Lukiw WJ, Cui JG, Musto AE, Musto BC, Bazan NG. Epileptogenesis in diacylglycerol kinase epsilon deficiency up-regulates COX-2 and tyrosine hydroxylase in hippocampus. Biochem Biophys Res Commun 338: 77–81, 2005. [DOI] [PubMed] [Google Scholar]
- 23.Masoodi M, Nicolaou A. Lipidomic analysis of twenty-seven prostanoids and isoprostanes by liquid chromatography/electrospray tandem mass spectrometry. Rapid Commun Mass Spectrom 20: 3023–3029, 2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Merida I, Avila-Flores A, Merino E. Diacylglycerol kinases: at the hub of cell signalling. Biochem J 409: 1–18, 2008. [DOI] [PubMed] [Google Scholar]
- 25.Milne SB, Ivanova PT, Armstrong MD, Myers DS, Lubarda J, Shulga YV, Topham MK, Brown HA, Epand RM. Dramatic differences in the roles in lipid metabolism of two isoforms of diacylglycerol kinase. Biochemistry 47: 9372–9379, 2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Morigi M, Galbusera M, Gastoldi S, Locatelli M, Buelli S, Pezzotta A, Pagani C, Noris M, Gobbi M, Stravalaci M, Rottoli D, Tedesco F, Remuzzi G, Zoja C. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol 187: 172–180, 2011. [DOI] [PubMed] [Google Scholar]
- 27.Murakami M, Naraba H, Tanioka T, Semmyo N, Nakatani Y, Kojima F, Ikeda T, Fueki M, Ueno A, Oh S, Kudo I. Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 275: 32783–32792, 2000. [DOI] [PubMed] [Google Scholar]
- 28.Namkoong S, Lee SJ, Kim CK, Kim YM, Chung HT, Lee H, Han JA, Ha KS, Kwon YG, Kim YM. Prostaglandin E2 stimulates angiogenesis by activating the nitric oxide/cGMP pathway in human umbilical vein endothelial cells. Exp Mol Med 37: 588–600, 2005. [DOI] [PubMed] [Google Scholar]
- 29.Noris M, Mele C, Remuzzi G. Podocyte dysfunction in atypical haemolytic uraemic syndrome. Nat Rev Nephrol 11: 245–252, 2015. [DOI] [PubMed] [Google Scholar]
- 30.Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 361: 1676–1687, 2009. [DOI] [PubMed] [Google Scholar]
- 31.Ozaltin F, Li BH, Rauhauser A, An SW, Soylemezoglu O, Gonul II, Taskiran EZ, Ibsirlioglu T, Korkmaz E, Bilginer Y, Duzova A, Ozen S, Topaloglu R, Besbas N, Ashraf S, Du Y, Liang CY, Chen P, Lu DM, Vadnagara K, Arbuckle S, Lewis D, Wakeland B, Quigg RJ, Ransom RF, Wakeland EK, Topham MK, Bazan NG, Mohan C, Hildebrandt F, Bakkaloglu A, Huang CL, Attanasio M. DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN. J Am Soc Nephrol 24: 377–384, 2013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Pozzi A, Macias-Perez I, Abair T, Wei S, Su Y, Zent R, Falck JR, Capdevila JH. Characterization of 5,6- and 8,9-epoxyeicosatrienoic acids (5,6- and 8,9-EET) as potent in vivo angiogenic lipids. J Biol Chem 280: 27138–27146, 2005. [DOI] [PubMed] [Google Scholar]
- 33.Qi Z, Cai H, Morrow JD, Breyer MD. Differentiation of cyclooxygenase 1- and 2-derived prostanoids in mouse kidney and aorta. Hypertension 48: 323–328, 2006. [DOI] [PubMed] [Google Scholar]
- 34.Rao R, Redha R, Macias-Perez I, Su Y, Hao C, Zent R, Breyer MD, Pozzi A. Prostaglandin E2-EP4 receptor promotes endothelial cell migration via ERK activation and angiogenesis in vivo. J Biol Chem 282: 16959–16968, 2007. [DOI] [PubMed] [Google Scholar]
- 35.Riedl M, Fakhouri F, Le Quintrec M, Noone DG, Jungraithmayr TC, Fremeaux-Bacchi V, Licht C. Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches. Semin Thromb Hemost 40: 444–464, 2014. [DOI] [PubMed] [Google Scholar]
- 36.Rodriguez de Turco EB, Tang W, Topham MK, Sakane F, Marcheselli VL, Chen C, Taketomi A, Prescott SM, Bazan NG. Diacylglycerol kinase epsilon regulates seizure susceptibility and long-term potentiation through arachidonoyl- inositol lipid signaling. Proc Natl Acad Sci U S A 98: 4740–4745, 2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Schlondorff D, Ardaillou R. Prostaglandins and other arachidonic acid metabolites in the kidney. Kidney Int 29: 108–119, 1986. [DOI] [PubMed] [Google Scholar]
- 38.Smith WL, Langenbach R. Why there are two cyclooxygenase isozymes. J Clin Invest 107: 1491–1495, 2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Steffel J, Luscher TF, Ruschitzka F, Tanner FC. Cyclooxygenase-2 inhibition and coagulation. J Cardiovasc Pharmacol 47, Suppl 1: S15–S20, 2006. [DOI] [PubMed] [Google Scholar]
- 40.Stitt-Cavanagh EM, Faour WH, Takami K, Carter A, Vanderhyden B, Guan Y, Schneider A, Breyer MD, Kennedy CR. A maladaptive role for EP4 receptors in podocytes. J Am Soc Nephrol 21: 1678–1690, 2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Tang W, Bunting M, Zimmerman GA, McIntyre TM, Prescott SM. Molecular cloning of a novel human diacylglycerol kinase highly selective for arachidonate-containing substrates. J Biol Chem 271: 10237–10241, 1996. [PubMed] [Google Scholar]
- 42.Westland R, Bodria M, Carrea A, Lata S, Scolari F, Fremeaux-Bacchi V, D'Agati VD, Lifton RP, Gharavi AG, Ghiggeri GM, Sanna-Cherchi S. Phenotypic Expansion of DGKE-Associated Diseases. J Am Soc Nephrol 25: 1408–1414, 2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Xie C, Sharma R, Wang H, Zhou XJ, Mohan C. Strain distribution pattern of susceptibility to immune-mediated nephritis. J Immunol 172: 5047–5055, 2004. [DOI] [PubMed] [Google Scholar]
- 44.Zinellu A, Caria MA, Tavera C, Sotgia S, Chessa R, Deiana L, Carru C. Plasma creatinine and creatine quantification by capillary electrophoresis diode array detector. Anal Biochem 342: 186–193, 2005. [DOI] [PubMed] [Google Scholar]







